Position Paper of the Department of Hypertension of the Brazilian Society of Nephrology: Use of renin-angiotensin system blockers during the course of Covid-19 infection

ABSTRACT This position statement of the Department of Hypertension of the Brazilian Society of Nephrology (SBN) addresses the controversy surrounding the use or suspension/replacement of the renin-angiotensin-aldosterone system blockers (particularly inhibitors of the angiotensin-converting enzyme o...

Full description

Saved in:
Bibliographic Details
Published in:Brazilian Journal of Nephrology 2020-01, Vol.42 (2 suppl 1), p.47-48
Main Author: Rodrigues, Cibele Isaac Saad
Format: Article
Language:English
Subjects:
Coronavirus infections
Hypertension
Recommendations
Renin-Angiotensin System
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT This position statement of the Department of Hypertension of the Brazilian Society of Nephrology (SBN) addresses the controversy surrounding the use or suspension/replacement of the renin-angiotensin-aldosterone system blockers (particularly inhibitors of the angiotensin-converting enzyme or angiotensin II AT1 receptor blockers) prophylactically in individuals using these drugs, due to the possibility of allegedly worsening the prognosis of hypertensive patients infected with SARS-CoV-2. The SBN Hypertension Department recommends individualizing treatment and maintaining these medications until better scientific evidence is available. RESUMO Este posicionamento do Departamento de Hipertensão da Sociedade Brasileira de Nefrologia (SBN) trata da polêmica gerada em torno do uso ou da suspensão/substituição dos bloqueadores do sistema renina-angiotensina-aldosterona (particularmente inibidores da enzima de conversão da angiotensina ou bloqueadores dos receptores AT1da angiotensina II) profilaticamente em indivíduos que utilizam esses medicamentos, devido à possibilidade de supostamente piorar o prognóstico de pacientes hipertensos infectados pelo SARS-CoV-2. O Departamento de Hipertensão da SBN recomenda a individualização do tratamento e a manutenção dessas medicações até que melhores evidências científicas estejam disponíveis.
ISSN:0101-2800
2175-8239
DOI:10.1590/2175-8239-jbn-2020-s112